Pharma organisations underline Brexit concerns in letter to negotiators

The Association of the British Pharmaceutical Industry (ABPI) and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

23 July 2026 Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.

Pharma

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.

More features

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

AbbVie, Allergan takes on Swiss aesthetics rival over syringe design

Trump slaps 100% tariff on generic drugs in US manufacturing push

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

UK Prime Minister axes science ministry in govt shakeup

Masimo keeps $634m smartwatch award and moves to appeal

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

Why is 2026 already a record year for M&A activity?

Pharma organisations underline Brexit concerns in letter to negotiators

More on this story

Editor's picks

Editor's picks

More features